[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 15",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. The monthly compilation can be overwhelming -- read the weekly breakdown here.",
    "url": "https://finnhub.io/api/news?id=2e832e1e5fa61c3b6f60ceded0e1c936f98a15379c8005a027a9ac04d1556a4d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771007615,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of February 15",
      "id": 139090956,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. The monthly compilation can be overwhelming -- read the weekly breakdown here.",
      "url": "https://finnhub.io/api/news?id=2e832e1e5fa61c3b6f60ceded0e1c936f98a15379c8005a027a9ac04d1556a4d"
    }
  },
  {
    "ts": null,
    "headline": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
    "url": "https://finnhub.io/api/news?id=c6aab0163de6bd9e8ca8348b838a078a750a1d8b46fbf45ad1eb8a13a0afdfbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994661,
      "headline": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
      "id": 139085094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
      "url": "https://finnhub.io/api/news?id=c6aab0163de6bd9e8ca8348b838a078a750a1d8b46fbf45ad1eb8a13a0afdfbf"
    }
  },
  {
    "ts": null,
    "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
    "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
    "url": "https://finnhub.io/api/news?id=b1cffd6bc7d8cb84cb1a97c112ea52c9bda8409ed17002e316d6bd1889d92b41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770993360,
      "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
      "id": 139085046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
      "url": "https://finnhub.io/api/news?id=b1cffd6bc7d8cb84cb1a97c112ea52c9bda8409ed17002e316d6bd1889d92b41"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals",
    "summary": "Gilead Sciences offers a strong, sustainable dividend yield of 2.16%, backed by excellent profitability, a debt-free balance sheet, and a decade-long payment history.",
    "url": "https://finnhub.io/api/news?id=d5372bc3b73b532441f8f65e7d44fd2d8c339b0c2ff4e118706ea591f7cbb60a",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770985898,
      "headline": "Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals",
      "id": 139080172,
      "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
      "related": "GILD",
      "source": "ChartMill",
      "summary": "Gilead Sciences offers a strong, sustainable dividend yield of 2.16%, backed by excellent profitability, a debt-free balance sheet, and a decade-long payment history.",
      "url": "https://finnhub.io/api/news?id=d5372bc3b73b532441f8f65e7d44fd2d8c339b0c2ff4e118706ea591f7cbb60a"
    }
  },
  {
    "ts": null,
    "headline": "Pharma and biotech are back, says UBS' Michael Yee",
    "summary": "Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain Moderna's narrower-than-expected loss, why healthcare is outperforming, and vaccine mandates and more.",
    "url": "https://finnhub.io/api/news?id=c8f2f0ff1adda77891cf0c403ae16084d63bcc59265497359eee35af4db88140",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770983796,
      "headline": "Pharma and biotech are back, says UBS' Michael Yee",
      "id": 139086082,
      "image": "https://image.cnbcfm.com/api/v1/image/108265632-17709986291770998624-44006177752-1080pnbcnews.jpg?v=1770998628&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain Moderna's narrower-than-expected loss, why healthcare is outperforming, and vaccine mandates and more.",
      "url": "https://finnhub.io/api/news?id=c8f2f0ff1adda77891cf0c403ae16084d63bcc59265497359eee35af4db88140"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
    "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
    "url": "https://finnhub.io/api/news?id=b6b118ae18d1ab18ee2fb9ce783a92b9f61025c6d501d74c24fbf21bc908190a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770979202,
      "headline": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
      "id": 139079774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
      "url": "https://finnhub.io/api/news?id=b6b118ae18d1ab18ee2fb9ce783a92b9f61025c6d501d74c24fbf21bc908190a"
    }
  },
  {
    "ts": null,
    "headline": "3 Overrated  Stocks That Concern Us",
    "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
    "url": "https://finnhub.io/api/news?id=3f4e649654b672219d0c90a328f5ae4eb2ca43c177fa4f61f62f69966c7fcaee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770957791,
      "headline": "3 Overrated  Stocks That Concern Us",
      "id": 139089728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
      "url": "https://finnhub.io/api/news?id=3f4e649654b672219d0c90a328f5ae4eb2ca43c177fa4f61f62f69966c7fcaee"
    }
  }
]